References
- Galton D. A. G. The pathogenesis of chronic lymphocytic leukemia. Canadian Medical Association Journal 1966; 94: 1005–1017
- Dameshek W. Chronic lymphocytic leukemia — an accumulative disease of immunologically incompetent lymphocytes. Blood 1967; 29: 566–580
- Catovsky D., Foa R. The Lymphoid Leukaemias. Butterworths, London 1990
- Giles F. J., Worman C. P., Jewell A., Cawley J. C., Galvani D., Grant I. R., Hoffbrand A. V., Mehta A. B., Newland A. C., Goldstone A. H. Early results of alpha 2a interferon (Roferon) treatment of chronic lymphocytic leukaemia. British Journal of Haematology 1989; 74: S1–31
- Pangalis G. A., Griva E. Recombinant alpha-2b-interferon therapy in untreated stages A and B chronic lymphocytic leukemia. A preliminary report. Cancer 1988; 61: 869–874
- Rozman C., Montserrat E., Vinolas N. Recombinant alpha-2b-interferon in the treatment of B-chronic lymphocytic leukemia in early stages. Blood 1988; 71: 1295–1302
- Zeigler-Heitbrock H. W. L., Schlag R., Flieger D. Favorable response of early B-CLL patients to treatment with IFN alpha-2. Blood 1989; 73: 1426–1431
- Robertson M. J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421–2438
- Dransfield I., Cabanas G., Barrett J., Hogg N.
- Boyum A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. Scandinavian Journal of Clinical and Laboratory Investigation 1968; 21(Suppl. 97)51–76
- Kaplan M. E., Clark C. An improved rosetting assay for detection of human T lymphocytes. Journal of Immunological Methods 1974; 5: 131–137
- Trinchieri G. Biology of natural killer cells. Advances in Immunology 1989; 47: 187–376
- Wagner L., Goldstone A. H., Worman C. P. Demonstration of the increase in serine esterase-positive T cells in hairy-cell patients undergoing α-interferon therapy. Leukaemia 1989; 3: 373–379
- Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Leitman S., Leiman W. M., Robertson C. N., Lee R. E., Rubin J. T., Seipp C. A., Simpson C. G., White D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. New England Journal of Medicine 1987; 316: 889–897
- Foa R., Fierro M. T., Raspadori D., Bonferroni M., Cardona S., Guarini A., Gillio Tos A., Celle P., Cesano A., Matera L., Lauria F., Gavosto F. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: Defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors. Blood 1990; 76: 1349–1354
- Cemerlic D., Dadey B., Han T., Vaickus L. Cytokine influence on killing of fresh chronic lymphocytic leukaemia cells by human leucocytes. Blood 1991; 77: 2707–2715